{'fraction_non_alphanumeric': 0.029459901800327332, 'fraction_numerical': 0.02618657937806874, 'mean_word_length': 4.773584905660377, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.

A total of 139 HIV-infected adults failing a protease inhibitor (PI) regimen were recruited in a multicentre, prospective, open trial. All began saquinavir soft gel 1000 mg and ritonavir 100 mg twice a day plus two nucleoside analogues. Ten discontinued treatment because of adverse events. Plasma HIV-RNA levels fell > 1 log at 24 weeks in 44.5% of patients in an intent-to-treat analysis. The number of PI resistance mutations and saquinavir plasma levels independently predicted the virological response.